Navigation Links
Lifeline Biotechnologies and Depository Trust Company
Date:9/30/2011

RENO, Nev., Sept. 30, 2011 /PRNewswire/ -- Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) announced today that the Company continues efforts to reestablish DTC services.

Jim Holmes, Lifeline's CEO said "While our efforts have continued to reestablish DTC's services to the Company we have not been successful.  We now are considering alternatives should the circumstances not change.

The value of Lifeline is not reflected in the current lack of liquidity (low per share market price and low daily volume of shares traded).  Lifeline's investment in First Warning Systems has not diminished; in fact, First Warning's value has appreciated as established milestones have been achieved.  Our focus in First Warning is preparation for the final round of clinical trials estimated to commence in the latter half of 2012.   At this time, our best estimate for trial completion is late 2013. The trails must be successfully completed before our FDA medical device marketing application is submitted in the U.S."

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

CONTACT: Lifeline Biotechnologies, Inc.
Jim Holmes, 775-326-9614    Email: Jholmes@lbti.com    website: www.lbti.com


'/>"/>
SOURCE Lifeline Biotechnologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
2. Lifeline Skin Care™ Selects Click Here, Inc., Richards Partners
3. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
4. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
5. Benjamin Custodio Joins Millennium Biotechnologies to Expand International Sales
6. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
7. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
8. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
9. Andre Marion Joins Microchip Biotechnologies Board of Directors
10. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
11. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
Breaking Biology Technology:
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):